These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30768485)

  • 21. Synergistic Chromatin-Modifying Treatments Reactivate Latent HIV and Decrease Migration of Multiple Host-Cell Types.
    Blanco A; Mahajan T; Coronado RA; Ma K; Demma DR; Dar RD
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34201394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.
    Xing S; Bullen CK; Shroff NS; Shan L; Yang HC; Manucci JL; Bhat S; Zhang H; Margolick JB; Quinn TC; Margolis DM; Siliciano JD; Siliciano RF
    J Virol; 2011 Jun; 85(12):6060-4. PubMed ID: 21471244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infections.
    Yang H; Li X; Yang X; Lu P; Wang Y; Jiang Z; Pan H; Zhao L; Zhu Y; Khan IU; Shen Y; Lu H; Zhang T; Jiang G; Ma Z; Wu H; Zhu H
    Antiviral Res; 2019 Sep; 169():104555. PubMed ID: 31295520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy.
    Spivak AM; Andrade A; Eisele E; Hoh R; Bacchetti P; Bumpus NN; Emad F; Buckheit R; McCance-Katz EF; Lai J; Kennedy M; Chander G; Siliciano RF; Siliciano JD; Deeks SG
    Clin Infect Dis; 2014 Mar; 58(6):883-90. PubMed ID: 24336828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency.
    Covino DA; Desimio MG; Doria M
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui.
    Wang P; Lu P; Qu X; Shen Y; Zeng H; Zhu X; Zhu Y; Li X; Wu H; Xu J; Lu H; Ma Z; Zhu H
    Sci Rep; 2017 Aug; 7(1):9451. PubMed ID: 28842560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutics for HIV-1 reactivation from latency.
    Sgarbanti M; Battistini A
    Curr Opin Virol; 2013 Aug; 3(4):394-401. PubMed ID: 23810462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.
    Kim Y; Anderson JL; Lewin SR
    Cell Host Microbe; 2018 Jan; 23(1):14-26. PubMed ID: 29324227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents.
    Passaes CPB; Bruel T; Decalf J; David A; Angin M; Monceaux V; Muller-Trutwin M; Noel N; Bourdic K; Lambotte O; Albert ML; Duffy D; Schwartz O; Sáez-Cirión A
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.
    Leth S; Schleimann MH; Nissen SK; Højen JF; Olesen R; Graversen ME; Jørgensen S; Kjær AS; Denton PW; Mørk A; Sommerfelt MA; Krogsgaard K; Østergaard L; Rasmussen TA; Tolstrup M; Søgaard OS
    Lancet HIV; 2016 Oct; 3(10):e463-72. PubMed ID: 27658863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment.
    Relaño-Rodríguez I; Juárez-Sánchez R; Pavicic C; Muñoz E; Muñoz-Fernández MÁ
    J Nanobiotechnology; 2019 May; 17(1):69. PubMed ID: 31113488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
    Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
    J Virol; 2018 May; 92(10):. PubMed ID: 29343578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Interventions in HIV Cure Research.
    Rasmussen TA; Søgaard OS
    Adv Exp Med Biol; 2018; 1075():285-318. PubMed ID: 30030798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1.
    Martínez-Bonet M; Clemente MI; Serramía MJ; Muñoz E; Moreno S; Muñoz-Fernández MÁ
    Sci Rep; 2015 Nov; 5():16445. PubMed ID: 26563568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design.
    Ke R; Conway JM; Margolis DM; Perelson AS
    JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency.
    Hashemi P; Barreto K; Bernhard W; Lomness A; Honson N; Pfeifer TA; Harrigan PR; Sadowski I
    EMBO Mol Med; 2018 Feb; 10(2):160-174. PubMed ID: 29246970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
    Banga R; Procopio FA; Cavassini M; Perreau M
    J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency.
    Méndez C; Ledger S; Petoumenos K; Ahlenstiel C; Kelleher AD
    Retrovirology; 2018 Oct; 15(1):67. PubMed ID: 30286764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.